Today: 9 June 2026
Communication services stocks lag the rebound — what XLC investors need to know before Monday

Communication services stocks lag the rebound — what XLC investors need to know before Monday

NEW YORK, February 7, 2026, 13:21 (EST) — Market closed

Communication services names start the week lagging, as their flagship ETF, the Communication Services Select Sector SPDR Fund (XLC), lost 0.39% Friday, settling at $115.76.

Timing played a big role. While the S&P 500 jumped roughly 2% and nearly every sector climbed, Communication Services broke ranks—one of just two sectors to finish lower on Friday, a split traders didn’t miss. News Corp (NWSA) dragged the group down, shedding 6% to become its worst performer.

XLC leans heavily on a handful of names. Meta Platforms (META) accounts for just over 20% of the index, while Alphabet’s two share classes together contribute about another 20%, the fund’s latest top-holdings data show. Then come Verizon (VZ), AT&T (T), Comcast (CMCSA), and Netflix (NFLX), each at middling single-digit percentages.

Alphabet’s Class C shares (GOOG) slipped for a fourth consecutive session, losing 2.48% to close at $323.10 on Friday. Meta was also lower, dropping 1.31% to $661.46. The broader market looked much stronger: the S&P 500 added 1.97%, while the Dow surged 2.47% to end at 50,115.67.

One question keeps dogging investors: are tech giants pouring too much cash into “AI” — artificial intelligence — too fast? According to Reuters, big tech companies have plans for about $600 billion in capex by 2026. That number is spooking some, as worries about whether profits can keep pace pile up alongside surging AI infrastructure demand. “It’s a de-risking trade,” said Andrew Wells, chief investment officer at SanJac Alpha in Houston. Reuters

The Dow’s jump on Friday put a spotlight on the underlying tension rather than easing it. “What’s driven it recently has been the broadening that we have seen in the market … other than just the tech, AI trade,” said Chuck Carlson, chief executive officer at Horizon Investment Services. Reuters

Some comms stocks managed gains. Comcast finished up 1.69% at $31.37. Netflix picked up 1.64%, Disney tacked on 3.55%. Those moves helped soften losses from the internet giants.

Telecom stocks showed a mixed picture—Verizon slipped 1.68% to $46.31, AT&T edged down 0.66% to $27.13, and T-Mobile US (TMUS) lost 2.21%, closing at $197.39. That spread weighed on sector ETFs heavy on both carriers and internet platforms, keeping the group stuck in place.

Still, when the focus tightens on a few giants, it’s a double-edged sword. Alphabet and Meta lose ground again as investors question spending, and XLC risks slipping, even if the rest of the market holds up. Any hotter inflation number has the potential to drive Treasury yields up, putting more pressure on stocks that are sensitive to valuations.

Company news isn’t quiet next week either. T-Mobile will hold its Q4 2025 earnings call and provide a capital markets day update on Feb. 11, starting at 8:30 a.m. ET, per the investor relations schedule.

Both macro reports are set to drop close together. The U.S. Employment Situation report for January lands on Feb. 11 at 8:30 a.m. ET, while the Bureau of Labor Statistics has the January Consumer Price Index lined up for Feb. 13, also at 8:30 a.m. ET.

When markets open Monday, investors want to know if Friday’s split—surging indexes but lagging communication services—holds up. XLC faces a fast follow-up: jobs data, inflation numbers, and T-Mobile’s update all hit this week.

Stock Market Today

  • SailPoint Q1 Earnings Beat Estimates Amid Revenue Growth
    June 9, 2026, 10:14 AM EDT. SailPoint, Inc. (SAIL) reported Q1 earnings of $0.05 per share, surpassing the Zacks Consensus Estimate of $0.04 by 17.65%. Revenue increased to $280.14 million, beating estimates by 1.41% and up from $230.47 million a year ago. Despite earnings surprises and revenue growth, SailPoint shares have declined 12.6% year-to-date against the S&P 500's 8.2% rise. The company holds a Zacks Rank #3 (Hold), indicating expected market-aligned performance. Consensus estimates forecast Q2 EPS of $0.08 on $310.79 million revenue and fiscal year EPS of $0.32 on $1.27 billion revenue. Industry trends in the Zacks Internet-Software sector will influence future stock performance. Investors await management's commentary for guidance on sustainability.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes
Previous Story

Gold price near $5,000: China keeps buying as CME margin hikes raise the stakes

Shell stock: What to watch after PwC audit switch and Kazakhstan warning as buybacks roll on
Next Story

Shell stock: What to watch after PwC audit switch and Kazakhstan warning as buybacks roll on

Go toTop